BSEM BioStem Technologies Inc

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Program has honored more than 500 members of the military since its inception

Sponsorship honors both local military veterans and healthcare professionals

POMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the , announced today that they will celebrate the 13th season of the “” program throughout the upcoming 2025-26 NHL season with BioStem Technologies Inc. as the new sponsoring partner. Through the support of BioStem, the club will continue its special tradition of introducing and highlighting the important contributions of military veterans to the U.S. during all home games.

“As one of the MedTech industry anchors in South Florida, BioStem is proud to expand our partnership with the Florida Panthers as the sponsor of the ‘Heroes Among Us’ program to recognize and honor those whose military contributions have made a lasting difference to our country," said Jason Matuszewski, Chairman and CEO of BioStem Technologies.  “This sponsorship is an extension of our ongoing recognition of the sacrifices that our military members make, personified by our co-founder, Andrew Van Vurst, who is a veteran of the U.S. Marine Corps.”

Mr. Matuszewski continued, "We are also deeply honored to continue supporting the Panthers’ ‘Seats for Service’ program, which creates meaningful game-day experiences for veterans and their families. Together, these initiatives reflect our shared mission of giving back to those who have served, while also aligning with the upcoming launch of our American Amnion product line, a brand dedicated to advancing wound care for the military community.”

The “Heroes Among Us” program honors one military hero at every home game with a national anthem dedication and scoreboard video highlighting his or her story. Since its creation in 2013, the “Heroes Among Us” program has honored more than 500 local veterans and active-duty service members at Panthers’ home games, including more than 125 WWII veterans, 50 Vietnam War veterans, 20 Korean War veterans, and others.

“This program continues to be one of the most impactful moments of our games, as we honor the incredible stories of local veterans and recognize their service and sacrifice to our country,” said VP of Panthers Foundation & Community Relations, John Colombo. “It’s an honor to give our fans and community the opportunity to thank and appreciate these heroes on a nightly basis and appreciate BioStem Technologies’ support of this program.”

Nominate a Veteran for the “Heroes Among Us” Program:

The South Florida community can nominate a member of the military by visiting .

BioStem to Continue Sponsorship of the “Seats for Service” Program with the Panthers:

Additionally, BioStem will continue to support the “” initiative in partnership with the Panthers. The partnership initiated during the 2024-25 season and BioStem has supported 125 seats to date. Fans can to receive four tickets to a Panthers game at Amerant Bank Arena, one parking pass, and a $50 food and beverage credit. This initiative aims to create a memorable experience for the honorees and their families at Panthers games. Fans can nominate a veteran by clicking .

Florida Panthers Foundation:

One of the four core pillars of the Florida Panthers Foundation is veterans' affairs. The Panthers are dedicated to supporting organizations that provide critical resources and services to active duty and retired military members. For more information on the Panthers Foundation, please visit .

Purchase Tickets:

The Florida Panthers are back-to-back 2024 & 2025 Stanley Cup Champions! Fans interested in purchasing a Partial Plan for the 2025-26 season can click , visit , or by calling PUCK line (954.835.PUCK). 

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on , and .

About BioStem Technologies:

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit  and follow us on , and .

Contact BioStem Technologies, Inc.:

Website: 

E-Mail: 

X: 

Facebook: 

Phone: 954-380-8342

Investor Relations:

Adam Holdsworth, BioStem Director of Investor Relations

E-Mail: 

Phone: 954-854-2409

Or

Gilmartin Group:

Philip Trip Taylor, Principal

E-Mail: 

Phone: 415-937-5406



EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Expands Partnership with the Florida Panthers as ...

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program Program has honored more than 500 members of the military since its inceptionSponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the , announced today that they will celebrate the 13th season of the “” program through...

 PRESS RELEASE

BioStem Showcasing its Leading BioREtain® Technology at the Symposium ...

BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the Symposium for A...

 PRESS RELEASE

BioStem Technologies to Present at Two Upcoming Investor Conferences

BioStem Technologies to Present at Two Upcoming Investor Conferences POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY. Morgan Stanley Global Healthcare Conference: Format: Fireside ChatDate: Monday, September 8, 2025Time: 3:20 PM ET H.C. Wainwright 27th Annual Global Investment Conference: Format:...

 PRESS RELEASE

BioStem Technologies Announces Insider Share Purchase by Chairman and ...

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were made through two separat...

 PRESS RELEASE

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the healthcare sectorCompleted enrollment in ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch